In animal models, E1-deleted human adenoviral recombinants of the serotype 5 (AdHu5) have shown high efficacy as vaccine carriers for different Ags including those of HIV-1. Humans are infected by common serotypes of human adenovirus such as AdHu5 early in life and a significant percentage has high levels of neutralizing Abs to these serotypes, which will very likely impair the efficacy of recombinant vaccines based on the homologous virus. To circumvent this problem, a novel replication-defective adenoviral vaccine carrier based on an E1-deleted recombinant of the chimpanzee adenovirus 68 (AdC68) was developed. An AdC68 construct expressing a codon-optimized, truncated form of gag of HIV-1 induces CD8(+) T cells to gag in mice which at the height of the immune response encompass nearly 20% of the entire splenic CD8(+) T cell population. The vaccine-induced immune response provides protection to challenge with a vaccinia gag recombinant virus. Induction of transgene-specific CD8(+) T cells and protection against viral challenge elicited by the AdC68 vaccines is not strongly inhibited in animals preimmune to AdHu5 virus. However, the response elicited by the AdHu5 vaccine is greatly attenuated in AdHu5 preimmune animals.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4049/jimmunol.170.3.1416 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
E2A, VA RNA I, and L4-22k adenoviral helper genes are sufficient for AAV production in HEK293 cells.
Mol Ther Methods Clin Dev
December 2024
Schepens Eye Research Institute, Mass Eye and Ear Infirmary, Boston, MA, USA.
The replication-defective adeno-associated virus (AAV) is extensively utilized as a research tool or vector for gene therapy. The production process of AAV remains intricate, expensive, and mechanistically underexplored. With the aim of enhancing AAV manufacturing efficiencies in mammalian cells, we revisited the questions and optimization surrounding the requirement of the various adenoviral helper genes in enabling AAV production.
View Article and Find Full Text PDFSafety and immunogenicity of a ChAd155-vectored rabies vaccine compared with inactivated, purified chick embryo cell rabies vaccine in healthy adults.
Vaccine
December 2024
Hope Clinic, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.
Article Synopsis
- Rabies remains a high-mortality disease, prompting the exploration of a novel vaccine called ChAd155-RG, which uses a genetically modified chimpanzee adenovirus vector to improve immunization logistics.
- A phase 1 clinical trial involving healthy adults compared the safety and immune response of ChAd155-RG to the standard vaccine, RabAvert, assessing factors like side effects and antibody levels.
- Results showed that while ChAd155-RG was generally safe, it demonstrated lower and less lasting antibody responses against rabies compared to RabAvert, possibly influenced by participants' preexisting immunity to the adenovirus vector used in the vaccine.
Establishment of a novel cell line for producing replication-competent adenovirus-free adenoviruses.
BMC Biotechnol
September 2024
Laboratory of Microbiology and Immunology, College of Pharmacy, Inje University, 197 Injero, Gimhae, Gyeongnam, 50834, Republic of Korea.
Article Synopsis
- Adenoviruses are important tools in gene therapy and vaccine development, but their production poses challenges, particularly the risk of generating replication-competent adenoviruses (RCAs) in common cell lines like HEK293A.
- To address this issue, the study focused on creating a new cell line, L132, derived from human primary cells and enhanced by retroviral transduction.
- The newly developed GT541 cell line shows promise as an effective alternative to HEK293A for producing RCA-free adenoviruses.
Clinical Application of Adenovirus (AdV): A Comprehensive Review.
Viruses
July 2024
Department of Molecular Biodefense Research, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan.
Adenoviruses are non-enveloped DNA viruses that cause a wide range of symptoms, from mild infections to life-threatening diseases in a broad range of hosts. Due to the unique characteristics of these viruses, they have also become a vehicle for gene-transfer and cancer therapeutic instruments. Adenovirus vectors can be used in gene therapy by modifying wild-type viruses to render them replication-defective.
View Article and Find Full Text PDFThe Cre/loxP-Based Recombinant HBV cccDNA System In Vitro and In Vivo.
Methods Mol Biol
July 2024
Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Fudan University, Shanghai, China.
Covalently closed circular DNA (cccDNA) exists as a stable episomal minichromosome in the nucleus of hepatocytes and is responsible for hepatitis B virus (HBV) persistence. We recently reported a technique involving recombinant cccDNA (rcccDNA) of HBV by site-specific DNA recombination. A floxed monomeric HBV genome was engineered into a precursor plasmid (prcccDNA) which was excised via Cre/loxP-mediated DNA recombination to form a 3.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!